Necitumumab - Eli Lilly and Company
At a glance
- Drug Originator ImClone Systems
- Drug Licenced by Nippon Kayaku
- Drug Class Antineoplastics; Fab fragments; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor inhibitors; T lymphocyte stimulants
- USA Patent Applicants ELI LILLY CO
- USA Patents 65
- BLAs 1
- International Patents 614
Disclaimer